LP
VRTX icon

Lloyd Park’s Vertex Pharmaceuticals VRTX Stock Holding History

Lloyd Park’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$459K Hold
1,586
– – 0.57% 50
2022
Q2 		$447K Hold
1,586
– – 0.47% 51
2022
Q1 		$414K Hold
1,586
– – 0.46% 51
2021
Q4 		$348K Buy
+1,586
New +$308K 0.19% 86

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lloyd Park's VRTX Position: Q3 2022 in Review

Lloyd Park held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2022 at 1,586 shares worth $459K. The position accounts for 0.57% of the portfolio, ranked #50.

Lloyd Park first reported a position in VRTX in Q4 2021 and has held it in 4 quarters since. 1,127 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • Lloyd Park held 1,586 shares of Vertex Pharmaceuticals worth $459K as of Q3 2022.
  • Lloyd Park left its Vertex Pharmaceuticals share count unchanged in Q3 2022.
  • Vertex Pharmaceuticals made up 0.57% of Lloyd Park's portfolio in Q3 2022, its #50 holding.
  • Lloyd Park first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • 1,127 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Lloyd Park's 13F filing for Q3 2022, filed 14 Nov 2022.